TY - JOUR
T1 - KLIFS
T2 - an overhaul after the first 5 years of supporting kinase research
AU - Kanev, Georgi K.
AU - de Graaf, Chris
AU - Westerman, Bart A.
AU - de Esch, Iwan J.P.
AU - Kooistra, Albert J.
PY - 2021/1/8
Y1 - 2021/1/8
N2 - Kinases are a prime target of drug development efforts with >60 drug approvals in the past two decades. Due to the research into this protein family, a wealth of data has been accumulated that keeps on growing. KLIFS-Kinase-Ligand Interaction Fingerprints and Structures-is a structural database focusing on how kinase inhibitors interact with their targets. The aim of KLIFS is to support (structure-based) kinase research through the systematic collection, annotation, and processing of kinase structures. Now, 5 years after releasing the initial KLIFS website, the database has undergone a complete overhaul with a new website, new logo, and new functionalities. In this article, we start by looking back at how KLIFS has been used by the research community, followed by a description of the renewed KLIFS, and conclude with showcasing the functionalities of KLIFS. Major changes include the integration of approved drugs and inhibitors in clinical trials, extension of the coverage to atypical kinases, and a RESTful API for programmatic access. KLIFS is available at the new domain https://klifs.net.
AB - Kinases are a prime target of drug development efforts with >60 drug approvals in the past two decades. Due to the research into this protein family, a wealth of data has been accumulated that keeps on growing. KLIFS-Kinase-Ligand Interaction Fingerprints and Structures-is a structural database focusing on how kinase inhibitors interact with their targets. The aim of KLIFS is to support (structure-based) kinase research through the systematic collection, annotation, and processing of kinase structures. Now, 5 years after releasing the initial KLIFS website, the database has undergone a complete overhaul with a new website, new logo, and new functionalities. In this article, we start by looking back at how KLIFS has been used by the research community, followed by a description of the renewed KLIFS, and conclude with showcasing the functionalities of KLIFS. Major changes include the integration of approved drugs and inhibitors in clinical trials, extension of the coverage to atypical kinases, and a RESTful API for programmatic access. KLIFS is available at the new domain https://klifs.net.
UR - http://www.scopus.com/inward/record.url?scp=85099428687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099428687&partnerID=8YFLogxK
U2 - 10.1093/nar/gkaa895
DO - 10.1093/nar/gkaa895
M3 - Article
C2 - 33084889
AN - SCOPUS:85099428687
SN - 0305-1048
VL - 49
SP - D562-D569
JO - Nucleic Acids Research
JF - Nucleic Acids Research
IS - D1
ER -
